3459 results about "Regimen" patented technology

A system and method is implemented with use of a mobile communication device and at least one sensor configured to sense a parameter associated with a user's physiology. One or more parameters associated with the user's physiology are sensed, the sensed one or more parameters defining physiological data associated with the user. The physiological data is analyzed relative to training regimen data, the training regimen data comprising one or both of range limits and durations associated with an exercise regimen. The physiological data is transferred to the mobile communication device, and the mobile communication device provides the physiological data in a form suitable for integration into an avatar representative of the user.

The invention relates to an indication device for assisting a patient to follow a self-care regimen. The device comprises a first display area comprising at least two of a first indicator representative of a first type of activity, and a second display area comprising at least two of a second indicator representative of a second type of activity. Each indicator has a first visual state and a second visual state and input means is provided allowing each indicator to be selected and to be switched from the first to the second visual state. The device further comprises controller means for controlling the display areas and the user input means.

Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.

A method and device for treating epilepsy are disclosed which provide for electrical, chemical or magnetic stimulation of certain areas of the brain to modulate neuronal activity of areas associated with symptoms of epilepsy. Deep brain stimulation is combined with vagus nerve stimulation to enhance symptomatic relief of the disorder. Some embodiments also employ a sensing capability to optimize the therapeutic treatment regimen.

A patient apparatus is configured to receive and analyze information regarding patient compliance with anticoagulation medication and self-test coagulation regimens related to anticoagulation therapy. In addition, a patient apparatus is configured to receive data from a patient, including physiological data, pathophysiological data, biological data, psychological data, neuropsychological data, and / or behavioral data. Utilizing the received patient data, a patient apparatus can modify a warfarin regimen using an algorithm contained within the apparatus. The apparatus can communicate the modified warfarin regimen to the patient and to third parties, such as remotely located healthcare providers. In addition, the apparatus can prompt a patient when to perform a self-test and can prompt a patient to seek immediate medical attention, or to directly contact medical help, when so warranted.

The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an A.beta..sub.42 lowering agent to a mammal under conditions in which levels of A.beta..sub.42 are selectively reduced, levels of A.beta..sub.38 are increased, and levels of A.beta..sub.40 are unchanged. The invention provides methods and materials for developing and identifying A.beta..sub.42 lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of A.beta..sub.42 lowering agents and antioxidants, A.beta..sub.42 lowering agents and non-selective secretase inhibitors, as well as A.beta..sub.42 lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing A.beta..sub.42 lowering agents, antioxidants, non-selective secretase inhibitors, and / or acetylcholinesterase inhibitors as well as instructions related to dose regimens for A.beta..sub.42 lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.

Methods and apparatus for testing of the efficacy of therapeutic stimulation of pelvic nerves or musculature to alleviate one of incontinence or sexual dysfunction are disclosed. A therapy delivery device is operable in a therapy delivery mode and a test mode and an evoked response detector is employed in the test mode to detect the evoked response to applied test stimuli. The test stimuli parameters of the test stimulation regimen are adjusted prior to delivery of each test stimulation regimen, and the evoked responses to the applied test stimulation regimens are compared to ascertain an optimal test stimulation regimen. The therapy stimulation regimen parameters are selected as a function of the test electrical stimulation parameters causing the optimal evoked response.

The present invention provides treatment regimens for treating diseased prostate tissue, including the steps of chemically ablating prostate tissue and coadministering an antiandrogen. In some embodiments, prostate tissue is chemically ablated by injection of ethanol, or an injectable gel comprising ethanol, into prostate tissue. Steroidal and non-steroidal antiandrogens are suitable antiandrogens. One suitable non-steroidal antiandrogen is bicalutamide. The treatment regimen is suitable for treatment of prostate tissue diseases including benign prostatic hyperplasia and prostatic carcinoma. The invention further provides a treatment regimen for treating benign prostatic hyperplasia, including the steps of damaging prostate tissue and coadministering an antiandrogen. Also provided by the present invention is a kit for treating a human male, including a means for necrosing prostate tissue, an antiandrogen drug, and a means for administering the antiandrogen drug. A kit including a first surgical device for delivering a chemoablation fluid to prostate tissue transurethrally, an antiandrogen drug such as bicalutamide, and a second surgical device for administering the antiandrogen drug, is further provided.

An integrated lancet and testing striplet for measuring a body analyte level in a health care regimen includes a skin piercing member and an analyte sensor coupled together.

Devices, systems and methods by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably reduced by activating baroreceptors. A baroreceptor activation device is positioned near a baroreceptor, for example a baroreceptor in the carotid sinus. A control system may be used to modulate the baroreceptor activation device. The control system may utilize an algorithm defining a stimulus regimen which promotes long term efficacy and reduces power requirements / consumption.

A cost estimation tool, preferably a handheld computer, prices and evaluates the financial impact of new residents' prior to admission. Immediate access to this information and built-in therapeutic substitution and clinical advisories provides the opportunity to optimize pharmaceutical regimens prior to admission. In addition, an abbreviated Resource Utilization Group (RUG) evaluation function provides a rapid assessment tool to project reimbursement under the Medicare Prospective Payment System (PPS). A user may enter a complete drug regimen and estimate the costs for the regimen. Similarly, managed care reimbursement from managed care organizations (MCOs) to be analyzed. Also, drug cost may be estimated through a MEDICAID Preferred Drug List database that identifies potential Non-Preferred drugs that may be non-compensable. The present invention further transmits results wirelessly to health care providers.

A repeat prescription ordering system for allowing patients requiring resupply of medication or medical products to access a server using a portable communications and data processing device such as a smart phone or personal digital assistant. The server supplies to the patient a list of medication and medical products which they are authorized to order. The patient can select the products required, and the order is logged by the server and allocated to a supplier for completion of the order. The server maintains an estimate of the amount of medication or medical product held by the patient, this being based on the prescribed dosage regimen and information entered by the patient on their usage and, optionally, on checks on their own health. The patient may be alerted when the estimate indicates that their supplies are running low. The estimate is allowed to go below zero, this implying a possible departure from the prescribed medication regimen.

Controlled-specimen-sampling oral devices are described, implanted or inserted into an oral cavity, built onto a prosthetic tooth crown, a denture plate, braces, a dental implant, or the like. The devices are replaced as needed. The controlled specimen sampling may be passive, based on a dosage form, or electro-mechanically controlled, for a high-precision, intelligent, specimen sampling. Additionally, the controlled sampling may be any one of the following: sampling in accordance with a preprogrammed regimen, sampling at a controlled rate, delayed sampling, pulsatile sampling, chronotherapeutic sampling, closed-loop sampling, responsive to a sensor's input, sampling on demand from a personal extracorporeal system, sampling regimen specified by a personal extracorporeal system, sampling on demand from a monitoring center, via a personal extracorporeal system, and sampling regimen specified by a monitoring center, via a personal extracorporeal system. Specimen collection in the oral cavity may be assisted or induced by a transport mechanism, such as any one of, or a combination of iontophoresis, electroosmosis, electrophoresis, electroporation, sonophoresis, and ablation. The oral devices require replacement at relatively long intervals of weeks or months. The oral devices and methods for controlled specimen sampling apply to humans and animals.

A method and device for treating a mood and / or anxiety disorder are disclosed which comprise electrical, chemical or magnetic stimulation of certain areas of the brain to modulate neuronal activity of areas associated with symptoms of mood disorders. In certain embodiments, deep brain stimulation is combined with cranial nerve stimulation to enhance symptomatic relief of the disorder. Certain embodiments also employ a sensing capability to optimize the therapeutic treatment regimen.

A system and method for improving compliance by a patient with a medical regimen that has been prescribed to the patient wherein utilizing computer and electronic communication systems, patient data is compared to pharmaceutical data to verify prescribed drug dosage and prescribed medication duration are within acceptable limits, any abnormalities found by the comparisons are reported to the treating physician who may then alter the medical regimen before authorizing dispensing of the prescribed drugs and providing drug taking information to the patient, and upon authorization being issued, the patient is scheduled to receive reminder notifications prior to the prescribed time for the prescribed drugs to be administered, as well as automatically notifying the prescription distribution service to deliver the prescribed drugs to the patient, and notifying the payor service to pay for the prescribed drugs.

A method and apparatus for treating persons suffering from an eating disorder includes direct or indirect stimulation of selected areas of the brain associated with a symptom of the eating disorder. The stimulation regimen is programmable to enable physician optimization of stimulation signal parameters to ameliorate at least one symptom of bulimia or another eating disorder. Certain embodiments employ deep brain stimulation and / or sensing together with cranial nerve stimulation and / or sensing.

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and / or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and / or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

The invention is a modular backup and retrieval system. The software modules making up the backup and retrieval system run independently, and can run either on the same computing devices or on different computing devices. The modular software system coordinates and performs backups of various computing devices communicating to the modules. At least one module on one of the computing devices acts as a system manager for a network backup regimen. A management component acts as a manager for the archival and restoration of the computing devices on the network. It manages and allocates library media usage, maintains backup scheduling and levels, and supervises or maintains the archives themselves through pruning or aging policies. A second software module acts as a manager for each particular library media.

The invention provides population models, methods, and algorithms for targeting a dosing regimen or compound selection to an individual patient. The methods and algorithms of the invention utilize population models that incorporate genotype information for genes encoding drug metabolizing enzymes for one or more compounds of interest. The methods allow integration of genotype information for one or more genes encoding a drug metabolizing enzyme, particularly a cytochrome P450 gene with patient data. The methods allow integration of genotype information and the effect of one or more compounds on one or more drug metabolizing enzymes. The methods allow iterative feedback of drug metabolizing data obtained from a patient into the process of generating a dosage regimen recommendation for a compound of interest for an individual patient.

Systems, methods and computer program products for guiding selection of a therapeutic treatment regimen or a preventive therapeutic treatment regimen are disclosed. The method comprises (A) providing to a computing device comprising a first knowledge base comprising information about a plurality of different methylation statuses at selected sites of the DNA in cells with a known disease or medical condition and / or healthy cells, a second knowledge base comprising a plurality of expert rules for evaluating and selecting a type of disease or medical condition based on the methylation status at selected sites of the DNA of a patient, (B) generating in said computing device a ranked listing of diseases or medical conditions based on the information about the methylation status at selected sites of the DNA of the patient, the first knowledge base and the second knowledge base.

In a first aspect, a method is provided that includes (1) receiving input indicating an objective for a user; (2) receiving input indicating a characteristic of the user; (3) determining an exercise regimen designed to cause the user having the inputted characteristic to achieve the objective when the exercise regimen is followed; and (4) determining a video game in which successful play of the video game requires performing the exercise regimen. The video game includes a game system adapted to monitor the user and to influence game play based upon the user performing the exercise regimen. Numerous other aspects are provided.

The invention provides compositions comprising, 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

A system for optimizing a patient's insulin dosage regimen over time, comprising at least a first memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen, and data inputs corresponding at least to the patient's blood-glucose-level measurements determined at a plurality of times, and a processor operatively connected to the at least first memory. The processor is programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the one or more components in the patient's present insulin dosage regimen in order to maintain the patient's future blood-glucose-level measurements within a predefined range.

A system and method for the efficient administration of health care plans, particularly as to the reduction and / or elimination of avoidable medical costs for select individuals who participate in the plan, is disclosed. Existing health care data is processed to determine an indication as to the relative desirability of an intervention in a plan participant's health care regimen. The data is also processed to determine the status of one or more flags, each of which potentially indicates the relative desirability of an intervention in a plan participant's health care regimen. A predictive model is used to determine the status of a flag relating to the likelihood of an insurance plan participant making a disability claim within a certain period of time. The information relating to desirability of an intervention in a plan participant's health care regimen, as well as a plan participant's medical information and claim history, is presented to case managers and / or health care providers in a user-friendly format

A method and device for treating epilepsy are disclosed which provide for electrical, chemical or magnetic stimulation of certain areas of the brain to modulate neuronal activity of areas associated with symptoms of epilepsy. Deep brain stimulation is combined with vagus nerve stimulation to enhance symptomatic relief of the disorder. Some embodiments also employ a sensing capability to optimize the therapeutic treatment regimen.